Pediatrik Otoimmün Ensefalit

Van Mater H. Pediatric inflammatory brain diseases: A diagnostic approach. Curr Opin Rheumatol. 2014;26(5): 553-561. doi:10.1097/BOR.0000000000000092

Dalmau J, Graus F. Antibody-Mediated Encephalitis. New England Journal of Medicine. 2018;378(9): 840-851. doi:10.1056/nejmra1708712

Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev. 2017;97(2): 839-887. doi:10.1152/PHYSREV.00010.2016

Cellucci T, Van Mater H, Graus F, et al. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurol Neuroimmunol Neuroinflamm. 2020;7(2). doi:10.1212/NXI.0000000000000663

McKeon A, Lennon VA. Paediatric autoimmune encephalopathies: A lot done, more to do. J Neurol Neurosurg Psychiatry. 2013;84(7): 709. doi:10.1136/jnnp-2012-304458

Suleiman J, Dale RC. The recognition and treatment of autoimmune epilepsy in children. Dev Med Child Neurol. 2015;57(5): 431-440. doi:10.1111/dmcn.12647

Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC. Immune therapy in autoimmune encephalitis: A systematic review. Expert Rev Neurother. 2015;15(12): 1391-1419. doi:10.1586/14737175.2015.1115720

Armangue T, Petit-Pedrol M, Dalmau J. Autoimmune encephalitis in children. J Child Neurol. 2012;27(11): 1460-1469. doi:10.1177/0883073812448838

Armangue T, Titulaer MJ, Málaga I, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis - Clinical analysis and novel findings in a series of 20 patients. Journal of Pediatrics. 2013;162(4). doi:10.1016/j.jpeds.2012.10.011

Byrne S, Walsh C, Hacohen Y, et al. Earlier treatment of nmdar antibody encephalitis in children results in a better outcome. Neurol Neuroimmunol Neuroinflamm. 2015;2(4): 1-3. doi:10.1212/NXI.0000000000000130

Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the california encephalitis project. Clinical Infectious Diseases. 2012;54(7): 899-904. doi:10.1093/cid/cir1038

Granerod J, Dphil A, Clewley JP, et al. Causes of encephalitis and diff erences in their clinical presentations in England: a multicentre, population-based prospective study. Published online 2010. doi:10.1016/S1473

De Bruijn MAAM, Bruijstens AL, Bastiaansen AEM, et al. Pediatric autoimmune encephalitis: Recognition and diagnosis. Neurol Neuroimmunol Neuroinflamm. 2020;7(3). doi:10.1212/NXI.0000000000000682

Bien CG, Vincent A, Barnett MH, et al. Immunopathology of autoantibody-associated encephalitides: Clues for pathogenesis. Brain. 2012;135(5): 1622-1638. doi:10.1093/brain/aws082

Dalmau J, Bataller L. Clinical and Immunological Diversity of Limbic Encephalitis: A Model for Paraneoplastic Neurologic Disorders.

Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and Antibodies to Synaptic and Neuronal Cell Surface Proteins.; 2011. www.neurology.org

Prüss H, Finke C, Höltje M, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol. 2012;72(6): 902-911. doi:10.1002/ana.23689

Prüss H. Postviral autoimmune encephalitis: Manifestations in children and adults. Curr Opin Neurol. 2017;30(3): 327-333. doi:10.1097/WCO.0000000000000445

Kamei S, Sekizawa T, Shiota H, et al. Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. J Neurol Neurosurg Psychiatry. 2005;76(11): 1544-1549. doi:10.1136/jnnp.2004.049676

Sellner J, Dvorak F, Zhou Y, et al. Acute and long-term alteration of chemokine mRNA expression after anti-viral and anti-inflammatory treatment in herpes simplex virus encephalitis. Neurosci Lett. 2005;374(3): 197-202. doi:10.1016/j.neulet.2004.10.054

Hardy D. Autoimmune Encephalitis in Children. Pediatr Neurol. 2022;132: 56-66. doi:10.1016/J.PEDIATRNEUROL.2022.05.004

Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic Limbic Encephalitis: Neurological Symptoms, Immunological Findings and Tumour Association in 50 Patients. Vol 123.; 2000.

Wang H. Anti-NMDA receptor encephalitis and vaccination. Int J Mol Sci. 2017;18(1). doi:10.3390/ijms18010193

Cabezudo-García P, Mena-Vázquez N, Estivill Torrús G, Serrano-Castro P. Response to immunotherapy in anti-IgLON5 disease: A systematic review. Acta Neurol Scand. 2020;141(4): 263-270. doi:10.1111/ane.13207

Desestret V, Pascual O, Honnorat J. A mouse model of autoimmune encephalitis. Brain. 2015;138(1): 5-8. doi:10.1093/brain/awu342

Titulaer MJ, Höftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014;75(3): 411-428. doi:10.1002/ana.24117

Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66(1): 11-18. doi:10.1002/ana.21756

Burr T, Barton C, Doll E, Lakhotia A, Sweeney M. N-Methyl-D-Aspartate Receptor Encephalitis Associated With COVID-19 Infection in a Toddler. Pediatr Neurol. 2021;114: 75-76. doi:10.1016/j.pediatrneurol.2020.10.002

Armangue T, Spatola M, Vlagea A, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018;17(9): 760-772. doi:10.1016/S1474-4422(18)30244-8

Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. Lancet Neurol. 2013;12(2): 157-165. doi:10.1016/S1474-4422(12)70310-1

Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 2014;13(2): 167-177. doi:10.1016/S1474-4422(13)70282-5

Nosadini M, Thomas T, Eyre M, et al. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021;8(5). doi:10.1212/NXI.0000000000001052

Nosadini M, Granata T, Matricardi S, et al. Relapse risk factors in anti-N-methyl-D-aspartate receptor encephalitis. Dev Med Child Neurol. 2019;61(9): 1101-1107. doi:10.1111/dmcn.14267

Dhamija R, Renaud DL, Pittock SJ, et al. Neuronal Voltage-Gated Potassium Channel Complex Autoimmunity in Children. Pediatr Neurol. 2011;44(4): 275-281. doi:10.1016/J.PEDIATRNEUROL.2010.10.015

Haberlandt E, Bast T, Ebner A, et al. Limbic encephalitis in children and adolescents. Arch Dis Child. 2011;96(2): 186-191. doi:10.1136/adc.2010.183897

López-Chiriboga AS, Klein C, Zekeridou A, et al. LGI1 and CASPR2 neurological autoimmunity in children. Ann Neurol. 2018;84(3): 473-480. doi:10.1002/ana.25310

Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: A novel glycine receptor antibody. Neurology. 2008;71(16): 1291-1292. doi:10.1212/01.wnl.0000327606.50322.f0

Martinez-Martinez P, Molenaar PC, Losen M, De Baets MH. Glycine receptor antibodies in PERM: A new channelopathy. Brain. 2014;137(8): 2115-2116. doi:10.1093/brain/awu153

Quek AML, O’Toole O. Encephalitis associated with autoantibodies binding to γ-aminobutyric acid-A, γ-aminobutyric acid-B and glycine receptors: Immunopathogenic mechanisms and clinical characteristics. Neuroimmunol Neuroinflamm. 2016;3(3): 86-92. doi:10.4103/2347-8659.170633

Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: A case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol. 2014;13(3): 276-286. doi:10.1016/S1474-4422(13)70299-0

Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA B receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Published online 2010: 67. doi:10.1016/S1474

Höftberger R, Titulaer MJ, Sabater L, et al. Encephalitis and GABA B Receptor Antibodies Novel Findings in a New Case Series of 20 Patients.; 2013.

Jeffery OJ, Lennon VA, Pittock SJ, Gregory JK, Britton JW, Mckeon A. GABA B Receptor Autoantibody Frequency in Service Serologic Evaluation.; 2013.

Lancaster E, Martinez-Hernandez E, Titulaer M, et al. Antibodies to Metabotropic Glutamate Receptor 5 in the Ophelia Syndrome From the Departments of Neurology ( Supplemental Data at Www.Neurology.Org Supplemental Data Podcast.; 2011. www.neurology.org

Peschl P, Bradl M, Höftberger R, Berger T, Reindl M. Myelin oligodendrocyte glycoprotein: Deciphering a target in inflammatory demyelinating diseases. Front Immunol. 2017;8(MAY). doi:10.3389/fimmu.2017.00529

Hegen H, Reindl M. Recent developments in MOG-IgG associated neurological disorders. Ther Adv Neurol Disord. 2020;13. doi:10.1177/1756286420945135

Hacohen Y, Absoud M, Deiva K, et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm. 2015;2(2):e81. doi:10.1212/NXI.0000000000000081

Armangue T, Olivé-Cirera G, Martínez-Hernandez E, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol. 2020;19(3): 234-246. doi:10.1016/S1474-4422(19)30488-0

Wegener-Panzer A, Cleaveland R, Wendel EM, et al. Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies. Neurol Neuroimmunol Neuroinflamm. 2020;7(4). doi:10.1212/NXI.0000000000000731

Martinez-Hernandez E, Guasp M, García-Serra A, et al. Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Neurology. 2020;94(22):E2302-E2310. doi:10.1212/WNL.0000000000009239

Waters P, Fadda G, Woodhall M, et al. Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children with Demyelinating Syndromes. JAMA Neurol. 2020;77(1): 82-93. doi:10.1001/jamaneurol.2019.2940

Hacohen Y, Wong YY, Lechner C, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody–Associated disease. JAMA Neurol. 2018;75(4): 478-487. doi:10.1001/jamaneurol.2017.4601

Flanagan EP, Hinson SR, Lennon VA, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients. Ann Neurol. 2017;81(2): 298-309. doi:10.1002/ana.24881

Fang H, Hu W, Jiang Z, et al. Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy in Children: A Retrospective Analysis of 35 Cases. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.761354

Oxon D, JELLINEK DM Oxon EH, BALL Lond K. HASHIMOTO’S DISEASE AND ENCEPHALOPATHY LORD BRAIN. Vol 62.; 1957.

Zhou JY, Xu B, Lopes J, Blamoun J, Li L. Hashimoto encephalopathy: literature review. Acta Neurol Scand. 2017;135(3): 285-290. doi:10.1111/ane.12618

Lee J, Yu HJ, Lee J. Hashimoto encephalopathy in pediatric patients: Homogeneity in clinical presentation and heterogeneity in antibody titers. Brain Dev. 2018;40(1): 42-48. doi:10.1016/j.braindev.2017.07.008

Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4): 391-404. doi:10.1016/S1474-4422(15)00401-9

Adams A V., Mooneyham GLC, Van Mater H, Gallentine W. Evaluation of Diagnostic Criteria for Hashimoto Encephalopathy Among Children and Adolescents. Pediatr Neurol. 2020;107: 41-47. doi:10.1016/J.PEDIATRNEUROL.2019.12.011

Laurent C, Capron J, Quillerou B, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT): Characteristics, treatment and outcome in 251 cases from the literature. Autoimmun Rev. 2016;15(12): 1129-1133. doi:10.1016/J.AUTREV.2016.09.008

Mattozzi S, Sabater L, Escudero D, et al. Hashimoto encephalopathy in the 21st century. Neurology. 2020;94(2): E217-E224. doi:10.1212/WNL.0000000000008785

Langer JE, Lopes MBS, Fountain NB, et al. An unusual presentation of anti-Hu-associated paraneoplastic limbic encephalitis. Dev Med Child Neurol. 2012;54(9): 863-866. doi:10.1111/j.1469-8749.2012.04221.x

Hardy D. Autoimmune Encephalitis in Children. Pediatr Neurol. 2022;132: 56-66. doi:10.1016/J.PEDIATRNEUROL.2022.05.004

Mrabet S, Ben Achour N, Kraoua I, et al. Anti-Ma2-encephalitis in a 2 year-old child: A newly diagnosed case and literature review. European Journal of Paediatric Neurology. 2015;19(6): 737-742. doi:10.1016/J.EJPN.2015.06.005

Vinke AM, Schaper FLWVJ, Vlooswijk MCG, et al. Anti-GAD antibodies in a cohort of neuropsychiatric patients. Epilepsy & Behavior. 2018;82: 25-28. doi:10.1016/J.YEBEH.2018.03.004

Akman CI, Patterson MC, Rubinstein A, Herzog R. Limbic encephalitis associated with anti-GAD antibody and common variable immune deficiency. Dev Med Child Neurol. 2009;51(7): 563-567. doi:10.1111/j.1469-8749.2008.03217.x

Mishra N, Rodan LH, Nita DA, Gresa-Arribas N, Kobayashi J, Benseler SM. Anti-glutamic acid decarboxylase antibody associated limbic encephalitis in a child: Expanding the spectrum of pediatric inflammatory brain diseases. J Child Neurol. 2014;29(5): 677-683. doi:10.1177/0883073813500527

Korff CM, Parvex P, Cimasoni L, et al. Encephalitis Associated With Glutamic Acid Decarboxylase Autoantibodies in a Child A Treatable Condition? http://www.archneurol.com

Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: Diagnostic clues for this association. Brain. 2008;131(10): 2553-2563. doi:10.1093/brain/awn183

Varadkar S, Bien CG, Kruse CA, et al. Rasmussen’s encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol. 2014;13(2): 195-205. doi:10.1016/S1474-4422(13)70260-6

Bien CG, Granata T, Antozzi C, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: A European consensus statement. Brain. 2005;128(3): 454-471. doi:10.1093/brain/awh415

Gadian J, Eyre M, Konstantoulaki E, et al. Neurological and cognitive outcomes after antibody-negative autoimmune encephalitis in children. Dev Med Child Neurol. 2022;64(5): 649-653. doi:10.1111/dmcn.15101

Blinder T, Lewerenz J. Cerebrospinal fluid findings in patients with autoimmune encephalitis-a systematic analysis. Front Neurol. 2019;10(JUL). doi:10.3389/fneur.2019.00804

Haberlandt E, Ensslen M, Gruber-Sedlmayr U, et al. Epileptic phenotypes, electroclinical features and clinical characteristics in 17 children with anti-NMDAR encephalitis. European Journal of Paediatric Neurology. 2017;21(3): 457-464. doi:10.1016/J.EJPN.2016.11.016

Abboud H, Probasco JC, Irani S, et al. Autoimmune encephalitis: Proposed recommendations for symptomatic and long-term management. J Neurol Neurosurg Psychiatry. 2021;92(8):897-907. doi:10.1136/jnnp-2020-325302